Title:
HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS
Document Type and Number:
WIPO Patent Application WO/2024/041559
Kind Code:
A1
Abstract:
The invention is directed to a series of novel heterobicyclic amide derivatives as EP4 receptor antagonists which are useful for treating diseases or conditions mediated by the action of PGE2 at EP4 receptors, such as pain, an inflammatory disease and cancer. Also within the scope of this invention are pharmaceutical compositions containing such compounds and methods of use of these compounds for treating a subject suffering from a condition mediated by the action of PGE2 at EP4 receptors.
More Like This:
Inventors:
BAO JIANMING (CN)
QUAN WEIGUO (CN)
GAO YING-DUO (CN)
SUN YONGKUI (CN)
QUAN WEIGUO (CN)
GAO YING-DUO (CN)
SUN YONGKUI (CN)
Application Number:
PCT/CN2023/114414
Publication Date:
February 29, 2024
Filing Date:
August 23, 2023
Export Citation:
Assignee:
SHENZHEN IONOVA LIFE SCIENCE CO LTD (CN)
FOSHAN IONOVA BIOTHERAPEUTICS CO INC (CN)
GUANGDONG TOUCHSTONE TRANSLATIONAL RES INSTITUTE CO LTD (CN)
FOSHAN IONOVA BIOTHERAPEUTICS CO INC (CN)
GUANGDONG TOUCHSTONE TRANSLATIONAL RES INSTITUTE CO LTD (CN)
International Classes:
C07D495/04; A61K31/407; A61P29/00; A61P35/00
Domestic Patent References:
| WO2022161422A1 | 2022-08-04 |
Foreign References:
| CN102149384A | 2011-08-10 | |||
| CN111727044A | 2020-09-29 | |||
| CN111936502A | 2020-11-13 |
Attorney, Agent or Firm:
BEIJING DINGJIADA IP FIRM (CN)
Download PDF: